AMD Clinical Trials

5 recruiting

Frequently Asked Questions

Common questions about AMD clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 25 trials

Recruiting

Cell Collection to Study Eye Diseases

Retinal DegenerationRetinitis PigmentosaRetinal Disease+1 more
National Eye Institute (NEI)930 enrolled1 locationNCT01432847
Recruiting
Phase 3

Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)

Neovascular Age-Related Macular Degeneration (nAMD)Wet AMD
Adverum Biotechnologies, Inc.284 enrolled2 locationsNCT07482176
Recruiting
Phase 3

Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR)

Neovascular Age-Related Macular Degeneration (nAMD)Wet AMD
Innostellar Biotherapeutics Co.,Ltd332 enrolled31 locationsNCT07317934
Recruiting

Prognostic Role of Macular Neovascular Membrane Subtype in Pneumatic Displacement of Macular Hemorrhages

AMD - Age-Related Macular Degeneration
Marco Mazzola60 enrolled1 locationNCT07427160
Recruiting
Phase 2Phase 3

Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD

AMDnAMD
AbbVie630 enrolled89 locationsNCT04704921
Recruiting
Phase 3

Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

Neovascular Age-Related Macular Degeneration (nAMD)
4D Molecular Therapeutics480 enrolled43 locationsNCT07064759
Recruiting
Not Applicable

Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Macular Degeneration

Age-Related Macular DegenerationAMD
VisionCare, Inc.76 enrolled13 locationsNCT04796545
Recruiting
Phase 3

A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)

Neovascular Age-related Macular DegenerationnAMD
Hoffmann-La Roche68 enrolled16 locationsNCT05562947
Recruiting
Not Applicable

Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration

Age-Related Macular DegenerationIntermediate AMDAge-related Macular Degeneration (ARMD)
i-Lumen Scientific AUS PTY LTD100 enrolled9 locationsNCT06662162
Recruiting
Phase 1Phase 2

A Phase 1/2 Study to Evaluate the Safety and Efficacy of Intravitreal Administration of BS01 in Patients With Geographic Atrophy Secondary to Dry AMD

Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD)
Bionic Sight LLC40 enrolled1 locationNCT07158775
Recruiting

Detection and Management of Sinusitis in a Single-center Prospective Cohort of Patients With Exudative AMD (SINE)

AMD
Fondation Ophtalmologique Adolphe de Rothschild200 enrolled1 locationNCT05547633
Recruiting
Phase 2

A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO

Neovascular Age-Related Macular Degeneration (NVAMD)Branch Retinal Vein Occlusion (BRVO)
EyeBiotech Ltd.160 enrolled49 locationsNCT07205887
Recruiting
Phase 3

Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration

Neovascular Age-Related Macular Degeneration (nAMD)Wet AMD
Adverum Biotechnologies, Inc.284 enrolled79 locationsNCT06856577
Recruiting
Phase 1Phase 2

Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration

Geographic AtrophyAge-Related Macular DegenerationNon-neovascular AMD
Perceive Biotherapeutics, Inc.60 enrolled11 locationsNCT06087458
Recruiting
Phase 3

Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD

AMDnAMD
AbbVie660 enrolled181 locationsNCT05407636
Recruiting
Phase 1Phase 2

Multicenter, Phase I/II Study to Evaluate the Safety, Tolerability, PK and Efficacy of SCT520FF in Patients With nAMD

nAMD
Sinocelltech Ltd.82 enrolled1 locationNCT06672536
Recruiting

"My Eyes, My Light": Amar Chokh, Amar Alo

MyopiaDiabetic Retinopathy (DR)Presbyopia+6 more
Data Yakka, Inc.20,000 enrolled1 locationNCT07135570
Recruiting
Not Applicable

Progression Suppression and Retinal Regression in VEGF-resistant AMD

Neovascular Age-related Macular Degeneration (AMD)
PharmaBio Corporation10 enrolled1 locationNCT07005323
Recruiting

Lutein by Scleral Iontophoresis in AMD

Stage 3 AMD
Federico II University80 enrolled1 locationNCT06925893
Recruiting

Visual Rehabilitation and Depression in Visually Impaired Patients with AMD

AnxietyDepression DisordersAMD - Age-Related Macular Degeneration
Fondazione G.B. Bietti, IRCCS22 enrolled1 locationNCT06906003